Skip to content
DataLookout
Menu

NCT07479797

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Site details revised at 42 of 42 sites
  2. Notable Eligibility criteria expanded, about 51 words
    • Trial sites expanded: 19 → 42 locations
    • Secondary endpoints: details revised at 4 of 11 entries
  3. Minor Trial sites expanded: 14 → 19 locationsv8
  4. Minor Trial sites expanded: 10 → 14 locationsv7
  5. Minor Trial sites expanded: 2 → 10 locationsv6
  6. Minor Study sites: 1 to 2
    • Start date changed from estimate of Aug 2026 to May 22, 2026
    v5
  7. Notable Recruitment opened
    • Study sites: 0 to 1
    v4
  8. Notable Eligibility criteria shortened, about 21 wordsv2
  9. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Participants in Complete Response (CR) at Month 6
Timeframe: Month 6
Event-free survival (EFS)
Timeframe: Up to 36 months

Secondary (11)

Objective Response Rate (ORR)
Progression-Free Survival (PFS)
Duration of Response (DOR)
Duration of Complete Response (DOCR)
Overall Survival (OS)
Show 6 moreShow less
Percentage of Participants Experiencing Adverse Events (AEs)
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Cancer-30 (EORTC-QLQ-C30)
Changes From Baseline in the 5-level EuroQol 5 Dimensions Questionnaire (EQ-5D-5L) Score
Changes From Baseline in the EuroQol Visual Analogue Scale (EQ-VAS) Score
Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ)-Non-Hodgkin's lymphoma (NHL)-Non-Hodgkin Lymphoma High Grade Module 29 (HG29)

Arms and interventions

Lymphodepleting Chemotherapy: KITE-753Experimental

Participants with r/r LBCL will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine and cyclophosphamide. * A single infusion at a target dose of anti-cluster of differentiation 19 (CD19)/CD20 chimeric antigen receptor (CAR) T cells/kg of KITE-753.

Lymphodepleting Chemotherapy: Axicabtagene Ciloleucel (axi-cel)Experimental

Participants with r/r LBCL will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine and cyclophosphamide. * A single infusion at a target dose of anti-CD19/CD20 CAR T cells/kg of axi-cel.

Drugs: KITE-753, Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide

Sites

42 sites in 9 countries

United States 21, Spain 6, Australia 3, Canada 3, United Kingdom 3, Belgium 2, Japan 2, France 1, Germany 1